Understanding ISL1-DT: A Potential Drug Target and Biomarker (G642366)

Target Name: ISL1-DT

NCBI ID: G642366

ISL1-DT

Other Name(s): ISL1 divergent transcript

Understanding ISL1-DT: A Potential Drug Target and Biomarker

ISL1-DT, also known as ISL1-Divergent Transcript, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. ISL1-DT is derived from the ISL1 gene, which is located on chromosome 16 and has been shown to play a role in various cellular processes, including cell growth, differentiation, and survival.

The ISL1 gene has four splice variants, ISL1-DT1, ISL1-DT2, ISL1-DT3, and ISL1-DT4, which result in the production of different ISL1-DT molecules. ISL1-DT1 is the most abundant splice variant and is predominantly expressed in the brain, while ISL1-DT2 and ISL1-DT3 are predominantly expressed in the lungs and heart, respectively. ISL1-DT4 is the least abundant splice variant and is mainly expressed in the liver.

ISL1-DT has been shown to play a role in various cellular processes, including cell growth, differentiation, and survival. It has been shown to promote the growth and survival of cancer cells and has been used as a potential cancer therapeutic. ISL1-DT has also been shown to play a role in the development and progression of various diseases, including neurodegenerative disorders, respiratory diseases, and cardiovascular diseases.

ISL1-DT has been shown to interact with a variety of proteins, including TGF-β1, NF-kappa-B, and AP-1. It has been shown to modulate the expression of various genes, including cyclin D1, p21, and p53. ISL1-DT has also been shown to play a role in regulating cellular signaling pathways, including the PI3K/Akt signaling pathway.

ISL1-DT has been shown to be involved in a variety of diseases and conditions, including cancer, neurodegenerative disorders, respiratory diseases, and cardiovascular diseases. It has been shown to be a potential drug target and biomarker for these diseases and has been the subject of extensive research.

In addition to its potential clinical applications, ISL1-DT has also been shown to have potential implications for basic research. ISL1-DT has been shown to play a role in the regulation of various cellular processes and has been used to study the effects of various drugs and therapeutic agents on these processes. ISL1-DT has also been used to study the role of different splice variants of the ISL1 gene in the development and progression of various diseases.

Overall, ISL1-DT is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases. Further research is needed to fully understand its role in these processes and to develop effective treatments for these diseases.

Protein Name: ISL1 Divergent Transcript

The "ISL1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ISL1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets